Terminating a Distributor Agreement in Russia Requires Pharma Companies to Comply with GDP and Pharmacovigilance Rules
A partnership with a distributor built over five or seven years can collapse in a single commercial court (arbitrazh) session. The reason rarely lies in the text of the contract itself. Far more often, it stems from how the parties behaved in the final months leading up to the breach: what letters were sent, how much notice was given, and what was done with the remaining inventory in the warehouse.
For a pharmaceutical company, the price of an error is higher than in most other industries. In addition to a lawsuit seeking damages, Good Distribution Practice (GDP) guidelines and pharmacovigilance regulations come into play: a distributor terminating operations remains a participant in the drug supply chain down to the very last unit sold.
How Relationships with Distributors Were Formerly Terminated
Prior to 2022, distribution contracts in Russia operated under flexible rules. The Civil Code of the Russian Federation contains no dedicated chapter on distribution; for years, this contract existed as an unnamed contract (Clause 2, Article 421 of the Civil Code) or a mixed contract (Clause 3, Article 421 of the Civil Code), combining elements of supply, agency, and provision of services.
It is frequently qualified as a framework contract under Article 429.1 of the Civil Code: general terms remain effective even if specific deliveries are executed via separate purchase orders. Termination usually occurred by mutual agreement of the parties or via simple notice.
Disputes rarely reached the courts. The costs of litigation often exceeded the claim amounts, and a public conflict frightened both sides more than a potential loss.
The situation evolved alongside the market. Sanctions pressure, the restructuring of supply chains, and rising regulatory requirements from the Eurasian Economic Union (EAEU) regarding the circulation of medicines rendered the former model of gentlemen’s agreements unviable.
Which Method of Termination to Choose and Its Risks
Russian law offers three pathways to exit a distribution agreement, each carrying its own price tag.
Mutual agreement of the parties remains the safest option. Problems usually arise after signing: without a clear inventory audit procedure, the distributor can continue selling off residual inventory, creating a conflict with a new partner in the same market.
Unilateral refusal under Article 450.1 of the Civil Code applies if such a right is explicitly set out in the contract. Courts in 2024-2026 scrutinize notice periods more strictly: if the distributor managed to invest in warehousing, staff, and brand promotion, a 30-day exit window may be deemed insufficient, leading the court to declare the refusal made in bad faith under Article 10 of the Civil Code. Courts typically consider a period from 3 months to a year a reasonable notice period for distribution.
Judicial termination under Article 450 of the Civil Code requires proving a material breach. Case law recognizes systematic failure to meet agreed purchasing plans, price dumping that undermines brand positioning, and violations of mandatory GDP requirements as valid grounds.
| Termination Method | Legal Basis | Primary Risk |
|---|---|---|
| Mutual agreement of the parties | Art. 450 of the Civil Code (general principle) | Unresolved issue regarding residual inventory |
| Unilateral refusal | Art. 450.1 of the Civil Code | Refusal deemed made in bad faith due to a short notice period |
| Judicial termination | Art. 450 of the Civil Code | Lengthy proceedings, need to prove materiality of the breach |
The Weak Party in Distribution as a New Argument Against the Manufacturer
Special attention should be given to Article 428 of the Civil Code on adhesion contracts. For a long time, this provision was applied primarily to consumer disputes, but Resolution No. 16 of the Plenum of the Supreme Arbitrazh Court of the Russian Federation (SAC RF) dated March 14, 2014, extended its logic to relations between commercial organizations.
The mechanism works as follows: if a large manufacturer imposes a standard-form contract on a regional distributor without room to negotiate terms, and the agreement itself contains blatantly onerous clauses, for example the manufacturer’s right to terminate the relationship at any time while denying the distributor an equivalent right, the court may recognize the distributor as the weaker party. The consequence of such recognition is the right to challenge unfair terms or demand that the contract be amended.
Pharmaceutical distributors invest heavily in GDP infrastructure and staff training to meet the requirements of a specific manufacturer. This argument has become a real lever during negotiations over compensation amounts once a dispute reaches court.
GDP and Pharmacovigilance During a Change of Distributor
For medicinal products, terminating a distribution contract is not just a legal procedure. The EAEU Good Distribution Practice Rules, approved by Decision No. 80 of the Council of the Eurasian Economic Commission (EEC) dated November 3, 2016, require distributors to evaluate drug recipients not only before starting cooperation but on a regular basis throughout the entire term of the agreement.
In practice, even when ending a relationship, the distributor must verify the legality of the operations of counterparties to whom residual inventory is transferred and retain records of that verification. Separately, Decision No. 80 requires the distributor to investigate deviations in the supply chain of narcotic and psychotropic drugs and notify the competent authorities of the member states.
Pharmacovigilance is governed by separate rules. Council of the EEC Decision No. 87 dated November 3, 2016, establishes that the marketing authorization holder bears sole responsibility for establishing and maintaining the pharmacovigilance system master file (PSMF), even if some tasks are delegated to a distributor or another organization under contract. PSMF documents must be kept for at least 5 years after the system they describe is discontinued. Drug safety data must be kept longer, for at least 10 years after the marketing authorization is discontinued.
Changing a distributor or an authorized representative often requires revising the registration dossier. Council of the EEC Decision No. 117 dated November 29, 2024, established the procedure for drug registration initiated by the competent authority of a member state, including access to the dossier when procedure participants change.
Trademarks and the Price of a Legal Mistake
Use of a trademark after a relationship ends remains a separate risk area. Under Article 1487 of the Civil Code, rights to a trademark are deemed exhausted with respect to goods the rights holder has already put into circulation. A distributor may sell off legally acquired residual inventory even after the contract is terminated.
The situation is different for use of a logo in advertising, on signage, or in a domain name. Without a license agreement registered with Rospatent under Article 1490 of the Civil Code, such rights are considered not granted, and a former partner who keeps using the brand risks a lawsuit. When setting the amount of compensation, courts often rely on the position of the Constitutional Court of the Russian Federation in Resolution No. 28-P dated December 13, 2016, which allows compensation to be reduced below the statutory minimum set by the Civil Code based on the actual circumstances of the case, including the proportionality of the breach and the nature of the defendant’s activities.
The financial consequences of a failed breakup keep growing year after year. According to research by the law firm Nerra, in 2025 and early 2026 courts satisfied 51% of claims for damages against company directors, with total awards reaching 32.5 billion rubles, up from 3.8 billion rubles in 2016. Most such disputes arise in services, construction, manufacturing, and trade, a category that includes distribution.
A separate trend concerns the subsidiary liability of controlling persons in a counterparty’s bankruptcy. According to Fedresurs data, in the first half of 2025 courts satisfied 61% of applications to hold controlling persons subsidiarily liable, with the average recovery exceeding 88 million rubles.
What to Do
Check the basis for termination. Determine whether the contract grants a right of unilateral refusal (Art. 450.1 of the Civil Code) or whether you will need to prove a material breach in court (Art. 450 of the Civil Code). Your entire course of action depends on this choice.
Build your evidence file in advance. Document failures to meet purchasing plans, payment delays, and GDP deviations in writing, with proof of receipt by the distributor. Court practice in 2024-2026 requires documented evidence, not general claims of bad faith.
Send notice with a reasonable period. For pharmaceutical distribution, courts generally treat a notice period of 3 to 12 months as reasonable, depending on how much the partner invested in infrastructure and staff training.
Agree on the fate of residual inventory and pharmacovigilance data. Set out in the termination agreement the procedure for returning or selling off goods, and the procedure for transferring adverse-reaction data to the marketing authorization holder.
Resolve the trademark question before signing the termination act. Check that logos have been removed from the former partner’s websites and signage, and confirm that any license agreement, if one existed, was properly terminated with Rospatent.
A court dispute over the termination of a distribution agreement is rarely decided by the text of the contract. What usually decides it is how the parties behaved in the final months of the relationship: the notice period, the quality of the documentation, and whether the company managed to close out regulatory matters before going to court. For the pharmaceutical market, where ordinary contractual risks are compounded by GDP and pharmacovigilance requirements, preparing for a breakup should start months before it actually happens.
Regulatory Framework:
1. Resolution of the Plenum of the Supreme Arbitrazh Court of the Russian Federation (SAC RF) dated March 14, 2014, No. 16, «On Freedom of Contract and Its Limits»
2. Civil Code of the Russian Federation, Art. 10, 421, 428, 429.1, 450, 450.1, 1487, 1490
3. Decision of the Council of the EEC dated November 3, 2016, No. 80, «On Approval of the Good Distribution Practice Rules within the Eurasian Economic Union»
4. Decision of the Council of the EEC dated November 3, 2016, No. 87, «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union»
5. Decision of the Council of the EEC dated November 29, 2024, No. 117, «On Amendments to the Rules for Registration and Examination of Medicinal Products for Medical Use»
6. Resolution of the Constitutional Court of the Russian Federation dated December 13, 2016, No. 28-P